OnCore Login

Return to Trial Database

HCRN-GYN06-111

A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis

Status

Study Completed

Cancer Type(s)

Ovarian

Study Contact

Publications

A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer
  • D Matei, R Ramasubbaiah, J Schilder, SM Perkins, C Whalen, T Breen, CS Johnson, M Callahan, T Jones, G Sutton
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study
  • R Ramasubbaiah, SM Perkins, J Schilder, C Whalen, CS Johnson, M Callahan, T Jones, G Sutton, D Matei.

Trial Locations

All sites in which the trial HCRN-GYN06-111 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278